Non-financial reporting

Our social impact

How we contribute to a better tomorrow for all
Patient
Number of patients treated with Roche medicines (1)
•Number of patients treated with patented medicines
•Number of patients treated with off- patent medicines
Number of tests conducted with Diagnostics products (in billions)
Number of Roche medicines on the WHO list of essential medicines
Number of patients included in clinical trials (2)
- % of patients participating from low and low-middle income countries (3)
Number of new molecular entities (NMEs) in clinical development
Number of major regulatory filings completed (Pharmaceuticals)
Number of FDA Breakthrough Therapy designations
Number of new medicines launched (4)
Number of Diagnostics key product launches
Grants, Sponsorships and Donations to Healthcare and Patient Organisations (mCHF) (5) (6)
2021
16,357,184
1,402,100
14,955,084
27
32
244’517
1.46%
80
16
2
3
16
270 ✔ PwC CH
2020
28,868,306
2,286,113
26,582,193
23.4
32
235,186
1.14%
89
11
4
4
13
303
2019
37,307,100
1,701,965
35,605,135
24.5
32
234,579
1.26%
72
11
4
2
9
305
Employees
Number of employees (full-time equivalents - FTE) (7)
•Roche Pharmaceuticals
•Chugai Pharmaceuticals
•Diagnostics Division
•Corporate
% FTEs by Age Group:
• <30 years old
• 30-50 years old
• >50 years old
Percentage of total employees covered by collective bargaining agreements (8)(9)
Percentage of employees on part time
Percentage of women in total workforce (8)
Percentage of women in management (8)
Percentage of women on the Corporate Executive Committee
Percentage of women on the Board
Percentage of women in key leadership positions (8) (9) (10)
% of Underrepresented Nationalities in Executive Positions
Total number of new employee hires (9)
Internal recruitment rate (8)(9)
External recruitement rate (8)(9)
Employee total turnover rate (fluctuation) (9)
Percentage of voluntary turnover (9)
Percentage of Employer related Terminations (9)
Percentage of Employee related Terminations (9)
Average training hours per employee based on our Learning Management Systems (11)
Training costs per headcount (CHF)
Overall training costs (mCHF)
GEOS (employee survey) participation rate (12)
GEOS (employee survey) engagement rate (12)
Roche Accident Rate (on a yearly basis) (15)
Roche Illness Rate (on a yearly basis) (15)
Number of work related fatalities
Work-related accidents per 200,000 working hours (15)
Occupational accidents (15)
Occupational illnesses (15)
Lost workdays per year (15)
Roche Group Help & Advice Line Requests
Roche Group SpeakUp Line cases
Alleged Business Ethics Incidents
Number of employees terminated due to unethical behavior
Number of grievances about human rights impacts filed, addressed and resolved through formal grievance mechanism
100,920 ✔ PwC CH
46,889 ✔ PwC CH
7,711 ✔ PwC CH
39,266 ✔ PwC CH
7,054 ✔ PwC CH

11%
63%
25%
20.3% ✔ PwC CH
11.2% ✔ PwC CH
50.9% ✔ PwC CH
43.8% ✔ PwC CH
40.0% ✔ PwC CH
25.0% ✔ PwC CH
35.9% ✔ PwC CH
14.2%
10,346 ✔ PwC CH
72.4% ✔ PwC CH
27.6% ✔ PwC CH
11.3% ✔ PwC CH
6.6% ✔ PwC CH
41.6% ✔ PwC CH
58.4% ✔ PwC CH
45.0 ✔ PwC CH
1,075 ✔ PwC CH
113 ✔ PwC CH
78% ✔ PwC CH
80 ✔ PwC CH
0.040 ✔ PwC CH
0.011 ✔ PwC CH
0 ✔ PwC CH
0.285 ✔ PwC CH
270 ✔ PwC CH
140 ✔ PwC CH
4215 ✔ PwC CH
20
161
568
88
4
101,465
49,762
7,611
37,907
6,185

N/A
N/A
N/A
20.1%
11.1%
51.0%
44.0%
40.0%
25.0%
31.9%
N/A
11,394
67.4%
32.6%
7.7%
4.4%
42.6%
57.4%
35.0
1,077
114
na
na
0.042
0.011
0
0.297
277
148
4,369
21
181
646
178
11
97,735
48,012
7,448
37,114
5,161

N/A
N/A
N/A
17.0%
7.8%
49.3%
43.5%
20.0%
25.0%
32.0%
N/A
14,157
64.6%
35.4%
8.5%
5.2%
31.3%
61.8%
32.2
1,501
151
86%
68%
0.044
0.013
1
0.376
334
113
4,397
16
182
543
128
8
Suppliers
% of supplier agreements including the Roche Supplier Code of Conduct (or equivalent)
% of suppliers risk assessed
Number of supplier safety, health and environment (SHE) audits conducted with contract manufacturers (13)
Number of supplier sustainability audits (14)
Number of business partners terminated due to unethical behavior
100%
100%
39
26
8
90%
100%
60
38
5
na
na
84
76
13
Communities
Community support by area:
•Humanitarian and social projects (%)
•Science and education (%)
•Arts and culture (%)
•Community involvement (%)
93% ✔ PwC CH
3% ✔ PwC CH
3% ✔ PwC CH
1% ✔ PwC CH
90%
1%
6%
3%
90%
6%
2%
2%

    Our environmental impact

    How we minimize our impact on nature
    KPI
    Eco-balance (million impact points/employee) (15) (16) (17)
    Total energy consumption (TJ/year) - Scope 1, 2, 3 (Business flights only) (15)
    Greenhouse gas emissions (tonnes CO2 equivalents) - Scope 1, 2, 3 (Business flights only) (15)
    Water consumption (million cubic meters per year) (15)
    Organic matter discharged to water ways after treatment (t/year) (15)
    Heavy metals discharged to water ways after treatment (kg/year) (15)
    Hazardous waste (landfilled and incinerated waste in tonnes) (15) (18) (19)
    Non-Hazardous waste (landfilled and incinerated waste in tonnes) (15) (20)
    Energy intensity (GJ/employee) - Scope 1, 2, 3 (Business flights only) (15)
    Share (%) of sustainable electricity (15)
    CO2 intensity (t/employee) - Scope 1, 2, 3 (Business flights only) (15)
    Total number of SHE fines (significant) (15)
    2021
    5.22 ✔ PwC CH
    8,523 ✔ PwC CH
    438,187 ✔ PwC CH
    2.7 ✔ PwC CH
    76 ✔ PwC CH
    131 ✔ PwC CH
    15,110 ✔ PwC CH
    10,357 ✔ PwC CH
    81 ✔ PwC CH
    71.8% ✔ PwC CH
    4.16 ✔ PwC CH
    2 ✔ PwC CH
    2020
    5.6
    9,222
    502,755
    2.8
    76
    174
    13,332
    11,139
    89
    67.8%
    4.85
    0
    2019
    7.4
    11,822
    685,446
    3.1
    127
    228
    17,422
    10,500
    117
    69.5%
    7.08
    0

    Our economic impact

    How we invest in medical advances, create jobs and ensure livelihoods
    KPI
    Income taxes (mCHF)
    Income taxes as % of sales
    Sales (mCHF)
    Research and development core investments (mCHF) (21)
    Research and development as % of sales
    M&D costs (mCHF) (21)
    M&D as % of sales
    Core operating profit (mCHF) (21)
    Core operating profit margin (%) (21)
    Net financial income (mCHF) (21)
    IFRS Net Income (mCHF)
    Core Earnings Per Share (CHF)
    Operating free cash flow
    Operating free cash flow as % of sales
    Net debt (mCHF)
    Dividend per share (CHF) (22)
    Dividend (bnCHF) (22)
    Payout ratio (dividend per share divided by core EPS)
    Market capitalisation (CHF billions)
    2021
    3,075
    4.90%
    62,801
    13,708
    21.83%
    9,444
    15.04%
    21,897
    34.87%
    -751
    14,935
    20
    19,411
    30.91%
    -18,167
    9.3
    7.526
    47%
    307
    2020
    3,594
    6.16%
    58,323
    12,153
    20.84%
    9,361
    16.05%
    21,536
    36.93%
    -564
    15,068
    19.16
    14,815
    25.4%
    -1,882
    9.1
    7.849
    48%
    267
    2019
    3,515
    5.70%
    61,466
    11,696
    19.00%
    10,513
    17.10%
    22,479
    36.60%
    -903
    14,108
    20.16
    20,921
    34.00%
    2,505
    9
    7.763
    45%
    268

    The marked figures (✔ PwC CH) were reviewed by the PricewaterhouseCoopers auditing firm.

    (1) The patient number estimates how many treatments for specific diseases have been delivered in one year. It is based on the medicines sold and adjusted by average daily dose, treatment duration and compliance.

    (2) Patients included in all Roche sponsored/funded and supported (eg. IIS, collaborative group, partner) studies incl phase 1-5, where patients have been enrolled.

    (3) Based on the World Bank Country classifications , July 1st 2014.

    (4) Medicines launched in the US.

    (5) Change in methodology from cash based accounting until 2019 to the accrual based accounting in 2020 for our Grants Donations and Sponsorships.

    (6) Grants, Sponsorships and Donations to Healthcare and Patient Organisations are disclosed on a combined basis in 2021, and comparative years 2020 and 2019 have also been combined accordingly.

    (7) GenMark included in FTE values only.

    (8) Excluding Chugai due to the arm's length alliance agreement between Roche (a major shareholder) and Chugai to retain its autonomy.

    (9) Excluding Workday Light Companies (these companies do not use Workday as their leading HR system based on their merger/acquisition agreements).

    (10) Percentage of women in executive positions (Global Executives and Corporate Executive Committee) was revised in 2021 and shows an improved methodology.

    (11) Excluding Spark Therapeutics (no tracking of training hours).

    (12) GEOS is executed every second year excluding Workday Light Companies and Chugai. Due to the switch of the GEOS partner from AON Hewitt to GLINT a new methodology is applied to 2021 results.

    (13) Roche conducts safety, health, and environment (SHE) audits of Contract Manufacturing Organizations (CMOs) due to their higher SHE risk.

    (14) Roche sustainability audits are conducted per Pharmaceutical Supply Chain Initiative (PSCI) protocols and guidance. Roche is a PSCI member and the PSCI principles are embedded in our Supplier Code of Conduct.

    (15) Environmental data from Spark Therapeutics, Flatiron Health, and Foundation Medicine are not included in the Roche environmental results.

    (16) The Roche eco-balance refers to the consumption of energy and resources and the pollution caused by business activities. It thus describes the total environmental impact of our operations.

    (17) The 2019 and 2020 eco-balance are calculated using a revised and improved methodology compared to former years.

    (18) Contaminated soil is not included

    (19) The increase in 2021 in hazardous waste is due to the reallocation of electronic waste to hazardous waste.

    (20) Construction waste is not included.

    (21) Core results exclude non-core items such as global restructuring charges and amortisation and impairment of goodwill and intangible assets.

    (22) For the year 2021 as proposed by the Board of Directors.

    We create value for all our stakeholders and track our performance against key financial and non-financial indicators. These indicators are grouped under our main areas of engagement:

    Discover more